LncRNAs in tumor metabolic reprogramming and tumor microenvironment remodeling DOI Creative Commons
Jianhang Jiao,

Yangzhi Zhao,

Qimei Li

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Oct. 30, 2024

The tumor microenvironment (TME) is a complex and dynamic ecosystem composed of cells, immune supporting the extracellular matrix. Typically, TME characterized by an immunosuppressive state. To meet demands rapid proliferation, cancer cells undergo metabolic reprogramming, which enhances their biosynthesis bioenergy supply. Immune require similar nutrients for activation leading to competition immunosuppression within TME. Additionally, metabolites inhibit cell function. Consequently, immunosuppressed immune-tolerant promotes proliferation metastasis. Long non-coding RNAs (lncRNAs), category RNA longer than 200 nucleotides, regulate reprogramming interacting with key enzymes, transporters, related signaling pathways involved in metabolism. Furthermore, lncRNAs can interact both cellular non-cellular components TME, thereby facilitating growth, metastasis, drug resistance, inducing immunosuppression. Recent studies have demonstrated that play crucial role reshaping regulating reprogramming. In this discussion, we explore potential mechanisms through remodel examine prospects as targets anti-tumor therapy biomarkers prognosis.

Language: Английский

Tumor hypoxia: From basic knowledge to therapeutic implications DOI Creative Commons
Chengheng Liao, Xijuan Liu, Cheng Zhang

et al.

Seminars in Cancer Biology, Journal Year: 2023, Volume and Issue: 88, P. 172 - 186

Published: Jan. 1, 2023

Language: Английский

Citations

88
Current insight into the regulation of PD-L1 in cancer DOI Creative Commons

Zhuandi Liu,

Xibao Yu, Ling Xu

et al.

Experimental Hematology and Oncology, Journal Year: 2022, Volume and Issue: 11(1)

Published: July 30, 2022

Abstract The molecular mechanisms underlying cancer immune escape are a core topic in immunology research. Cancer cells can T cell-mediated cellular cytotoxicity by exploiting the inhibitory programmed cell-death protein 1 (PD-1)/programmed cell death ligand (PD-L1, CD274) checkpoint. Studying PD-L1 regulatory pattern of tumor will help elucidate evasion and improve treatment. Recent studies have found that regulate at transcriptional, post-transcriptional, post-translational levels influence anti-tumor response regulating PD-L1. In this review, we focus on regulation summarize mechanisms.

Language: Английский

Citations

63
Targeted Inhibition of lncRNA Malat1 Alters the Tumor Immune Microenvironment in Preclinical Syngeneic Mouse Models of Triple-Negative Breast Cancer DOI Creative Commons
Oluwatoyosi Adewunmi, Yichao Shen, Xiang H.-F. Zhang

et al.

Cancer Immunology Research, Journal Year: 2023, Volume and Issue: 11(11), P. 1462 - 1479

Published: Aug. 21, 2023

Abstract Long noncoding RNAs (lncRNA) play an important role in gene regulation both normal tissues and cancer. Targeting lncRNAs is a promising therapeutic approach that has become feasible through the development of gapmer antisense oligonucleotides (ASO). Metastasis-associated lung adenocarcinoma transcript (Malat1) abundant lncRNA whose expression upregulated several cancers. Although Malat1 increases migratory invasive properties tumor cells, its microenvironment (TME) still not well defined. We explored connection between immune (TIME) using immune-competent preclinical syngeneic Tp53-null triple-negative breast cancer (TNBC) mouse models mimic heterogeneity immunosuppressive TME found human Using ASO, we were able to knockdown RNA resulting delay primary growth, decreased proliferation, increased apoptosis. In addition, immunophenotyping tumor-infiltrating lymphocytes revealed inhibition altered TIME, with decrease tumor-associated macrophages (TAM) myeloid-derived suppressor cells (MDSC) as increase cytotoxic CD8+ T cells. depletion TAMs, MDSCs cytokine/chemokine secretion whereas inflammatory secretions T-cell proliferation. Combination ASO chemotherapy or checkpoint blockade (ICB) improved treatment responses model. These studies highlight immunostimulatory effects TNBC, benefit therapeutic, potential use combination chemotherapies immunotherapies.

Language: Английский

Citations

28
Long non-coding RNAs in cancer: multifaceted roles and potential targets for immunotherapy DOI
Lokesh Kadian, Deepika Verma, Neelam Lohani

et al.

Molecular and Cellular Biochemistry, Journal Year: 2024, Volume and Issue: 479(12), P. 3229 - 3254

Published: Feb. 28, 2024

Language: Английский

Citations

8
Biomarker discovery and application—An opportunity to resolve the challenge of liver cancer diagnosis and treatment DOI Creative Commons
Jingtao Chen, Chao Niu, Ning Yang

et al.

Pharmacological Research, Journal Year: 2023, Volume and Issue: 189, P. 106674 - 106674

Published: Jan. 23, 2023

Liver cancer is one of the most common malignancies, with severe morbidity and mortality. While considerable progress has been made in liver treatment, 5-year overall survival (OS) patients not improved significantly. Reasons include inadequate capability early screening diagnosis, a high incidence recurrence metastasis, degree tumor heterogeneity, an immunosuppressive microenvironment. Therefore, identification validation specific robust biomarkers are major importance for screening, timely accurate prognosis, prevention progression. In this review, we highlight some latest research potential applications biomarkers, describing hotspots prospective directions biomarker discovery.

Language: Английский

Citations

18
Role of LncRNA H19 in tumor progression and treatment DOI Creative Commons
Linjing Li, Yuting Gao, Boyi Yu

et al.

Molecular and Cellular Probes, Journal Year: 2024, Volume and Issue: 75, P. 101961 - 101961

Published: April 8, 2024

As one of the earliest discovered lncRNA molecules, H19 is usually expressed in large quantities during embryonic development and involved cell differentiation tissue formation. In recent years, role tumors has been gradually recognized. Increasing evidence suggests that its aberrant expression closely related to cancer development. LncRNA as an oncogene not only promotes growth, proliferation, invasion metastasis many tumors, but also develops resistance treatment, affecting patients' prognosis survival. Therefore, this review, we summarise extensive research on involvement tumor progression discuss how H19, a key target gene, affects sensitivity radiotherapy, chemotherapy immunotherapy by participating multiple cellular processes regulating signaling pathways, which provides promising prospect for further into treatment cancer.

Language: Английский

Citations

7
Long non-coding RNAs: Fundamental regulators and emerging targets of cancer stem cells DOI

Aboo Shabna,

S. Bindhya,

Chirukandath Sidhanth

et al.

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2023, Volume and Issue: 1878(3), P. 188899 - 188899

Published: April 25, 2023

Language: Английский

Citations

15
Long non-coding RNAs modulate tumor microenvironment to promote metastasis: novel avenue for therapeutic intervention DOI Creative Commons

Sana Khurshid Baba,

Sadaf Khursheed Baba,

Rashid Mir

et al.

Frontiers in Cell and Developmental Biology, Journal Year: 2023, Volume and Issue: 11

Published: June 13, 2023

Cancer is a devastating disease and the primary cause of morbidity mortality worldwide, with cancer metastasis responsible for 90% cancer-related deaths. multistep process characterized by spreading cells from tumor acquiring molecular phenotypic changes that enable them to expand colonize in distant organs. Despite recent advancements, underlying mechanism(s) limited requires further exploration. In addition genetic alterations, epigenetic have been demonstrated play an important role development metastasis. Long non-coding RNAs (lncRNAs) are considered one most critical regulators. By regulating signaling pathways acting as decoys, guides, scaffolds, they modulate key molecules every step such dissemination carcinoma cells, intravascular transit, metastatic colonization. Gaining good knowledge detailed basis lncRNAs may provide previously unknown therapeutic diagnostic patients disease. this review, we concentrate on mechanisms regulation metastasis, cross-talk metabolic reprogramming, modulating cell anoikis resistance, influencing microenvironment, interaction pre-metastatic niche formation. addition, also discuss clinical utility potential treatment. Finally, represent areas future research rapidly developing field.

Language: Английский

Citations

13
Tumor-infiltrating B cells: Their dual mechanistic roles in the tumor microenvironment DOI Open Access

Demin Xue,

Shaozhen Hu,

Runchen Zheng

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 179, P. 117436 - 117436

Published: Sept. 12, 2024

Language: Английский

Citations

5
Development of a Novel Prognostic Model for Lung Adenocarcinoma Utilizing Pyroptosis‐Associated LncRNAs DOI Creative Commons

Hongyan Bai,

Tiantian Li,

Lina Sun

et al.

Analytical Cellular Pathology, Journal Year: 2025, Volume and Issue: 2025(1)

Published: Jan. 1, 2025

Lung cancer is a highly prevalent and fatal that seriously threatens the safety of people in various regions around world. Difficulty early diagnosis strong drug resistance have always been difficulties treatment lung cancer, so prognosis has focus scientific researchers. This study used genotype-tissue expression (GTEx) genome atlas (TCGA) databases to obtain 477 adenocarcinoma (LUAD) 347 healthy individuals' samples as research subjects divided LUAD patients into low-risk high-risk groups based on prognostic risk scores. Differentially expressed gene (DEG) analysis was performed 25 pyroptosis-related genes obtained from GeneCards MSigDB tissues noncancerous individuals, seven were significantly different among them. Coexpression differential these long noncoding RNAs (lncRNAs) found three lncRNAs (AC012615.1, AC099850.3, AO0001453.2) had significant differences between tissues. We Cox regression least absolute shrinkage sum selection operator (LASSO) construct model for with (pRLs) analyzed value pRLs by Likaplan-Meier curve regression. The results show prediction good ability. In addition, we also studied tumor mutation burden (TMB), immune dysfunction rejection (TIDE), microenvironment scores groups. successfully established pRLs, which provides new insights lncRNA-based strategies.

Language: Английский

Citations

0